Otorhinolaryngosurgery Clinic, World Hearing Center, Institute of Physiology and Pathology of Hearing, Warsaw/Kajetany, Poland.
Teleaudiology and Screening Department, World Hearing Center, Institute of Physiology and Pathology of Hearing, Mokra 17 Street, Nadarzyn, 05-830, Warsaw/Kajetany, Poland.
Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3525-3534. doi: 10.1007/s00405-022-07265-2. Epub 2022 Feb 19.
(1) To assess the effectiveness and safety of a bone-conduction implant, the Bonebridge BCI 602, in adults with conductive or mixed hearing loss. (2) To investigate whether the Bonebridge BCI 602 is at least as effective as the Bonebridge BCI 601 in such patients.
The study group included 42 adults who had either conductive or mixed hearing loss. All patients underwent Bonebridge BCI 602 implant surgery. Before and after implantation, pure-tone audiometry, speech recognition tests (in quiet and noise), and free-field audiometry were performed. Word recognition scores were evaluated using the Polish Monosyllabic Word Test. Speech reception thresholds in noise were assessed using the Polish Sentence Matrix Test. Subjective assessment of benefits was done using the APHAB (Abbreviated Profile of Hearing Aid Benefit) questionnaire.
The APHAB questionnaire showed that difficulties in hearing decreased after BCI 602 implantation. Both word recognition in quiet and speech reception threshold in noise were significantly better after BCI 602 implantation and remained stable for at least 12 months. A significant advantage of the device is a reduced time for surgery while maintaining safety. In this study, the mean time for BCI 602 implantation was 28.3 min ± 9.4.
The second-generation Bonebridge BCI 602 implant is an effective hearing rehabilitation device for patients with conductive or mixed hearing loss. Patient satisfaction and audiological results confirm its efficacy and safety. Its new shape and dimensions allow it to be used in patients previously excluded due to insufficient or difficult anatomical conditions. The new BCI 602 implant is as effective as its predecessor, the BCI 601.
(1)评估骨导植入物 Bonebridge BCI 602 在传导性或混合性听力损失成人中的有效性和安全性。(2)研究 Bonebridge BCI 602 在这类患者中的效果是否至少与 Bonebridge BCI 601 相当。
研究组纳入了 42 名传导性或混合性听力损失的成年人。所有患者均接受 Bonebridge BCI 602 植入手术。植入前后进行纯音测听、语音识别测试(在安静和噪声环境中)和自由场测听。使用波兰单音节词测试评估单词识别得分。使用波兰句子矩阵测试评估噪声环境中的语音识别阈。使用 APHAB(助听器受益简化量表)问卷进行主观获益评估。
APHAB 问卷显示,植入 BCI 602 后听力困难程度降低。植入 BCI 602 后,安静环境下的单词识别和噪声环境下的语音识别阈均显著提高,且至少 12 个月内保持稳定。该设备的一个显著优势是手术时间缩短,同时保持安全性。在本研究中,BCI 602 植入的平均时间为 28.3 分钟±9.4 分钟。
第二代 Bonebridge BCI 602 植入物是传导性或混合性听力损失患者有效的听力康复装置。患者满意度和听力学结果证实了其疗效和安全性。其新的形状和尺寸使其可用于因解剖条件不足或困难而被排除的患者。新型 BCI 602 植入物与前代产品 BCI 601 一样有效。